| Ytd | -60.34% | |
| 1y | -16.51% |
| Open | 2.27 | Prev Close | 2.28 | Low | 2.13 | High | 2.29 | Mkt Cap | 239.24M |
| Vol | 678.78K | Avg Vol | 710.67K | EPS | -0.57 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-23 | 50-d Avg | 1.84 | 200-d Avg | 3.38 | 1yr Est | 0.00 |
NGEN News
VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage
Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See
HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a
Leerink Partners analyst Marc Goodman initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a O
NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA
U.S.$250,000,000Common SharesDebt SecuritiesSubscription ReceiptsWarrantsUnitsThe amended and restat
NGEN stock climbs as NervGen Pharma NVG-291 hits a 100% responder rate in spinal cord injury gait an
NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Gl
VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the
US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe
US stocks rise with the Dow gaining 250 points. Health care shares jump while energy stocks fall. BJ
Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Othe
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the
The offering is being made pursuant to a prospectus supplement to an amended and restated short form
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the
VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the
Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrade
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on NervGen Pharma (NASDAQ:N
NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ: NGEN), a clinical-stage b
VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or t
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or t
NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage bi
VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or t
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or t
NervGen Pharma Corp. demonstrates lasting functional improvements in chronic cervical spinal cord in
NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clini
NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV: NGEN) (NASDAQ: NGEN), a cli
VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or t
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or t
VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or th
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or th
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical da
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Gro